Angiotensin Converting Enzyme Inhibitors in Treatment of Covid 19

Tanta University

Status and phase: Not yet enrolling; Phase 3

Conditions: COVID

Treatments: Drug: Conventional treatment; Drug: ACEIs

Study type: Interventional

Funder types: Other

Identifiers

NCT04345406

ACEIS COVID 19

Details and patient eligibility

About

ACEIs as treatment for COVID19

Full description

ACEIs as suggested treatment for COVID19

Enrollment: 60 estimated patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients infected with covid 19

Exclusion criteria

• allergy or contraindications to the drug

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

60 participants in 2 patient groups

ACEIs

Experimental group

Description:

ACEIs with conventional treatment for COVID19

Treatment:

Drug: ACEIs

Drug: Conventional treatment

Conventional treatment of COVID19

Experimental group

Description:

Conventional treatment of COVID19

Treatment:

Drug: Conventional treatment